Everything below concerns Synaptogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-11. Numbers and descriptions here follow the published literature rather than marketing material.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
The exact serotonin receptors responsible for MDMA's entactogenic effects are unclear, but may include the serotonin 5-HT1A receptor, 5-HT1B receptor, and 5-HT2A receptor, as well as 5-HT1A receptor-mediated oxytocin release and consequent activation of the oxytocin receptor. The role of oxytocin in the effects of MDMA was demonstrated in people with arginine vasopressin deficiency (central diabetes insipidus), who have oxytocin deficiency and in whom MDMA fails to elevate oxytocin levels and shows greatly blunted entactogenic effects. Induction of dopamine release is thought to be importantly involved in the stimulant and euphoriant effects of MDMA, while induction of norepinephrine release and serotonin 5-HT2A receptor stimulation are believed to mediate its sympathomimetic effects. Activation of serotonin 5-HT1B and 5-HT2A receptors is also thought to be involved in the stimulant and euphoriant effects of MDMA, while serotonin 5-HT2C receptor activation is thought to constrain these effects and limit MDMA's reinforcing potential. Serotonin 5-HT2B receptor signaling appears to be required for MDMA-induced serotonin release and effects. MDMA has been associated with a unique subjective "magic" or euphoria that few or no other known entactogens are said to fully reproduce. The mechanisms underlying this property of MDMA are unknown, but it has been theorized to be due to a specific mixture and balance of pharmacological activities, including combined serotonin, norepinephrine, and dopamine release and direct serotonin receptor agonism.
The contaminated vegetable proteins were imported from China in 2006 and early 2007 and used as pet food ingredients. The process of identifying and accounting for the source of the contamination and for how the contaminant causes sickness was ongoing. The first recalls were announced by Menu Foods late on Friday, 16 March 2007 for cat and dog food products in the United States. By 30 March the United States began to ban imports of wheat gluten from China. The Chinese government responded on 4 April by categorically denying any connection to the North American food poisonings refusing to allow inspection of facilities suspected of producing contaminated products. However, on 6 April 2007, the Chinese government told the Associated Press they would investigate the source of the wheat gluten and by 23 April China gave permission to FDA investigators to enter the country. On 25 April Chinese authorities began to shut down and destroy the implicated factories and detain their managers. The following day, China's Foreign Ministry said it had banned the use of melamine in food products, admitting that products containing melamine had cleared customs while continuing to dispute the role of melamine in causing pet deaths. China also vowed to cooperate with U.S. investigators to find the "real cause" of pet deaths. The United States Senate held an oversight hearing on the matter by 12 April. The economic impact on the pet food market has been extensive, with Menu Foods losing roughly US$30 million alone from the recall.
Helene Langevin is an American medical scientist who served as the Director of the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH) between November 2018 and November 2025. She was a professor in the University of Vermont College of Medicine's Department of Neurological Sciences. She is best known for characterizing certain cellular and mechanical effects of acupuncture. She was also a Professor in Residence of Medicine at Harvard Medical School, Brigham and Women's Hospital. Prior to working at NIH, Langevin was the Director of the Osher Center for Integrative Medicine, jointly owned by Brigham and Women's Hospital and Harvard Medical School. Langevin was the principal investigator of studies funded by the National Institutes of Health. The Boston Globe describes her as a "celebrity" in the world of acupuncture.
== Gene expression assays == Reporter genes can be used to assay for the expression of a gene of interest that is normally difficult to quantitatively assay. Reporter genes can produce a protein that has little obvious or immediate effect on the cell culture or organism. They are ideally not present in the native genome to be able to isolate reporter gene expression as a result of the gene of interest's expression. To activate reporter genes, they can be expressed constitutively, where they are directly attached to the gene of interest to create a gene fusion. This method is an example of using cis-acting elements where the two genes are under the same promoter elements and are transcribed into a single messenger RNA molecule. The mRNA is then translated into protein. It is important that both proteins be able to properly fold into their active conformations and interact with their substrates despite being fused. In building the DNA construct, a segment of DNA coding for a flexible polypeptide linker region is usually included so that the reporter and the gene product will only minimally interfere with one another. Reporter genes can also be expressed by induction during growth. In these cases, trans-acting elements, such as transcription factors are used to express the reporter gene. Reporter gene assay have been increasingly used in high throughput screening (HTS) to identify small molecule inhibitors and activators of protein targets and pathways for drug discovery and chemical biology. Because the reporter enzymes themselves (e.g.
Sources: en.wikipedia.org
=== EC 1.3.3 With oxygen as acceptor === EC 1.3.3.1: dihydroorotate oxidase EC 1.3.3.2: Now EC 1.14.19.20 Δ7-sterol 5(6)-desaturase EC 1.3.3.3: coproporphyrinogen oxidase EC 1.3.3.4: protoporphyrinogen oxidase EC 1.3.3.5: bilirubin oxidase EC 1.3.3.6: acyl-CoA oxidase EC 1.3.3.7: dihydrouracil oxidase EC 1.3.3.8: tetrahydroberberine oxidase EC 1.3.3.9: Now EC 1.14.19.62 secologanin synthase EC 1.3.3.10: tryptophan a,b-oxidase EC 1.3.3.11: pyrroloquinoline-quinone synthase EC 1.3.3.12: l-galactonolactone oxidase
== Symptoms and signs == The experience of craniocervical instability can range from minor symptoms to severe disability, in which patients are bedbound. The constellation of symptoms caused by craniocervical instability is known as cervico-medullary syndrome, which may include:
== Taxonomic distribution and evolutionary advantages == Action potentials are found throughout multicellular organisms, including plants, invertebrates such as insects, and vertebrates such as reptiles and mammals. Sponges seem to be the main phylum of multicellular eukaryotes that does not transmit action potentials, although some studies have suggested that these organisms have a form of electrical signaling, too. The resting potential, as well as the size and duration of the action potential, have not varied much with evolution, although the conduction velocity does vary dramatically with axonal diameter and myelination.
Sources: en.wikipedia.org
== External links == MedlinePlus drug information - Aminoglycosides (Systemic) Science Daily Bacterial 'Battle for Survival' - Rhodostreptomycin Wikiversity page for the International Ototoxicity Management Group
The Greater Manchester Integrated Transport Authority (GMITA) was a local government institution responsible for the strategic direction of passenger transport in Greater Manchester. It existed from 1969 to 1974 as the SELNEC Passenger Transport Authority and was then replaced by Greater Manchester County Council. It was created again in 1986 as the Greater Manchester Passenger Transport Authority. It was renamed in 2008 as the Greater Manchester Integrated Transport Authority. Policy of the authority was delivered by the Greater Manchester Passenger Transport Executive. It was replaced by the Greater Manchester Combined Authority in 2011.
== External links == Adrenomedullin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human ADM genome location and ADM gene details page in the UCSC Genome Browser. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
==== Prokaryotic pathway ==== In prokaryotes such as bacteria, diphosphatidylglycerol synthase catalyses a transfer of the phosphatidyl moiety of one phosphatidylglycerol to the free 3'-hydroxyl group of another, with the elimination of one molecule of glycerol, via the action of an enzyme related to phospholipase D. The enzyme can operate in reverse under some physiological conditions to remove cardiolipin.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.